CoChat

Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease

Open access
Dwomoh, Louis, Tejeda, Gonzalo S., Tobin, Andrew B. · 2022 · Neuronal Signaling

The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) remains a major cause of morbidity and mortality worldwide, and despite extensive research, only a few drugs are available for management of the disease. One strategy has been to up-regulate cholinergic neurotransmission to improve cognitive function, but this approach has dose-limiting adverse effects. To avoid these adverse effects, new drugs that target specific receptor subtypes of the cholinergic system are needed, and the M1 subtype of muscarinic acetylcholine receptor (M1-mAChR) has been shown to be a good target for this approach. By using several strategies, M1-mAChR ligands have been developed and trialled in preclinical animal models and in human studies, with varying degrees of success. This article reviews the different approaches to targeting the M1-mAChR in AD and discusses the advantages and limitations of these strategies. The factors to consider in targeting the M1-mAChR in AD are also discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/ns20210004

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Common signalling transduction pathways of the five subtypes of the mAChR Activation of M1-, M3- or M5-mAChR results in coupling of the receptor to the Gq/11 family of G proteins. This coupling leads to activation of phospholipase C (PLC) enzyme, with subsequent mobilisation and release of calcium (Ca2+) from the intracellular stores to the cytosol. Activation of M2- or M4-mAChR results in coupling to the G0/I family of G proteins. This coupling leads to inhibition of adenylate cyclase enzyme, which results in decreased levels of cytosolic cAMP.
Figure 1 Common signalling transduction pathways of the five subtypes of the mAChR Activation of M1-, M3- or M5-mAChR results in coupling of the receptor to the Gq/11 family of G proteins. This coupling leads to activation of phospholipase C (PLC) enzyme, with subsequent mobilisation and release of calcium (Ca2+) from the intracellular stores to the cytosol. Activation of M2- or M4-mAChR results in coupling to the G0/I family of G proteins. This coupling leads to inhibition of adenylate cyclase enzyme, which results in decreased levels of cytosolic cAMP.CC BY · PubMed Central
Figure 2 Allosteric modulation at the M1-mAChR Binding of a ligand to the allosteric pocket of the M1-mAChR can have three effects. (A) A conformational change in the receptor, leading to a change in the binding affinity of the orthosteric-bound ligand, in this case, ACh for the receptor. (B) A broader conformational change, leading to a change (increase or decrease) in the potency of ACh toward a particular signalling response. (C) A direct agonist effect exerted by the allosteric ligand independent of the presence of the orthosteric-bound ligand, ACh.
Figure 2 Allosteric modulation at the M1-mAChR Binding of a ligand to the allosteric pocket of the M1-mAChR can have three effects. (A) A conformational change in the receptor, leading to a change in the binding affinity of the orthosteric-bound ligand, in this case, ACh for the receptor. (B) A broader conformational change, leading to a change (increase or decrease) in the potency of ACh toward a particular signalling response. (C) A direct agonist effect exerted by the allosteric ligand independent of the presence of the orthosteric-bound ligand, ACh.CC BY · PubMed Central
Figure 3 Chemical structures of M1-mAChR allosteric ligands developed by Merck PQCA and MK-7622 are based on the chemical scaffold of BQCA.
Figure 3 Chemical structures of M1-mAChR allosteric ligands developed by Merck PQCA and MK-7622 are based on the chemical scaffold of BQCA.CC BY · PubMed Central
Figure 4 Chemical structures of M1-mAChR allosteric ligands developed by Pfizer PF06827443 and PF-06764427 are based on the chemical scaffold of PF-06767832.
Figure 4 Chemical structures of M1-mAChR allosteric ligands developed by Pfizer PF06827443 and PF-06764427 are based on the chemical scaffold of PF-06767832.CC BY · PubMed Central
Figure 5 Chemical structures of M1-mAChR allosteric ligands developed by Vanderbilt University VU0453595 and VU6004256 are based on the chemical scaffold of VU0486846.
Figure 5 Chemical structures of M1-mAChR allosteric ligands developed by Vanderbilt University VU0453595 and VU6004256 are based on the chemical scaffold of VU0486846.CC BY · PubMed Central
Figure 6 Ligand-induced signalling bias at the M1-mAChR (A) ACh binds to the orthosteric pocket of the M1-mAChR to activate the receptor, resulting in induction of conformational changes within the receptor. This leads to coupling of the receptor to G proteins and β-arrestin with equivalent potencies, and subsequent activation of multiple signalling pathways downstream of G proteins and β-arrestin. (B) Binding of an ‘unbiased’ PAM-agonist to the M1-mAChR allosteric pocket potentiates coupling to G proteins and β-arrestin with equivalent potencies, but results in enhanced activation of multiple signalling pathways downstream of G proteins and β-arrestin. (C) Pilocarpine is biased towards G protein signalling over β-arrestin signalling, hence binding to the orthosteric pocket of the M1-mAChR results in receptor conformations that promote coupling to G proteins with greater potency than to β-arrestin. This results in activation of signalling pathways downstream of G proteins over β-arrestin.
Figure 6 Ligand-induced signalling bias at the M1-mAChR (A) ACh binds to the orthosteric pocket of the M1-mAChR to activate the receptor, resulting in induction of conformational changes within the receptor. This leads to coupling of the receptor to G proteins and β-arrestin with equivalent potencies, and subsequent activation of multiple signalling pathways downstream of G proteins and β-arrestin. (B) Binding of an ‘unbiased’ PAM-agonist to the M1-mAChR allosteric pocket potentiates coupling to G proteins and β-arrestin with equivalent potencies, but results in enhanced activation of multiple signalling pathways downstream of G proteins and β-arrestin. (C) Pilocarpine is biased towards G protein signalling over β-arrestin signalling, hence binding to the orthosteric pocket of the M1-mAChR results in receptor conformations that promote coupling to G proteins with greater potency than to β-arrestin. This results in activation of signalling pathways downstream of G proteins over β-arrestin.CC BY · PubMed Central
Figure 7 Linking M1-mAChR drug development to pathological stages of AD In the early stages of the disease when there is gradual loss of cholinergic neurons and modest depletion of ACh as well as MCI, use of ‘pure’ M1-PAMs may be a good strategy to potentiate the actions of ACh and improve cognitive function with minimal risk of adverse effects. With progression to the moderate stages of the disease, there is relatively increased loss of ACh coupled with more pronounced disruptions to cognitive and behavioural functions. At this stage, the use M1-mAChR PAM-agonists to simultaneously potentiate the actions of ACh and directly activate the receptors may be an ideal strategy. In the severe stages of AD, there is significant depletion of ACh and severe loss of cognitive function. Orthosteric or bitopic ligands could be ideal in ‘replacing’ the actions of the depleted ACh to improve cognitive function. In developing these strategies, it is important to assess the risk-benefit profile of these ligands in the context of the patient.
Figure 7 Linking M1-mAChR drug development to pathological stages of AD In the early stages of the disease when there is gradual loss of cholinergic neurons and modest depletion of ACh as well as MCI, use of ‘pure’ M1-PAMs may be a good strategy to potentiate the actions of ACh and improve cognitive function with minimal risk of adverse effects. With progression to the moderate stages of the disease, there is relatively increased loss of ACh coupled with more pronounced disruptions to cognitive and behavioural functions. At this stage, the use M1-mAChR PAM-agonists to simultaneously potentiate the actions of ACh and directly activate the receptors may be an ideal strategy. In the severe stages of AD, there is significant depletion of ACh and severe loss of cognitive function. Orthosteric or bitopic ligands could be ideal in ‘replacing’ the actions of the depleted ACh to improve cognitive function. In developing these strategies, it is important to assess the risk-benefit profile of these ligands in the context of the patient.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 145 references

Research works printed but not linked: 1

  1. Brannan, 2018, KarXT, a combination of the M1/M4 cholinergic receptor agonist xanomeline and trospium for the treatment of psychosis and cognitive impairment in schizophrenia: phase I studies

Cited by

See all 60

Metadata

Authors
Dwomoh, L., Tejeda, G. S., & Tobin, A. B.
Affiliations
University of Glasgow (GB)
Corresponding author
Dwomoh, Louis
Venue
Neuronal Signaling
Published
2022-04
Volume
6
Issue
1
Pages
NS20210004-NS20210004
ISSN
2059-6553 (ISSN-L)
OpenAlex
W4226325396
Cited by
60
References
146
Citations by year
2026: 15 · 2025: 14 · 2024: 20 · 2023: 8 · 2022: 3
FWCI
1.55
Type
journal article
Language
en
Open access
Locations
  • Neuronal Signaling (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
Alzheimer's disease, M1 muscarinic receptor, muscarinic receptor ligands, cholinergic neurotransmission, cognitive function, drug development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease. https://app.cochat.ai/papers/10.1042/ns20210004
The paper
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022). Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease. Neuronal Signaling. https://doi.org/10.1042/ns20210004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.